AGEN Share Price

Open 3.95 Change Price %
High 4.21 1 Day 0.15 3.80
Low 3.93 1 Week -0.76 -15.64
Close 4.10 1 Month 0.37 9.92
Volume 1112692 1 Year -0.59 -12.58
52 Week High 7.49
52 Week Low 2.61
AGEN Important Levels
Resistance 2 4.36
Resistance 1 4.25
Pivot 4.08
Support 1 3.95
Support 2 3.84
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Agenus Inc. (NASDAQ: AGEN)

AGEN Technical Analysis 4
As on 2nd Dec 2016 AGEN Share Price closed @ 4.10 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4.60 & Strong Sell for SHORT-TERM with Stoploss of 5.65 we also expect STOCK to react on Following IMPORTANT LEVELS.
AGEN Target for December
1st Target up-side 5.33
2nd Target up-side 6.17
3rd Target up-side 7.01
1st Target down-side 2.93
2nd Target down-side 2.09
3rd Target down-side 1.25
AGEN Other Details
Segment EQ
Market Capital 112052832.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.antigenics.com
AGEN Address
AGEN
3 Forbes Road
Lexington, MA 02421
United States
Phone: 781-674-4400
Fax: 781-674-4200
Interactive Technical Analysis Chart Agenus Inc. ( AGEN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Agenus Inc.
AGEN Business Profile
Agenus Inc., including its subsidiaries, (Agenus) is a biotechnology company focused on the development and commercialization of technologies to treat cancers and infectious diseases. The Company's core technology portfolio consists of its Saponin Platform (based on its saponin adjuvant based technologies) and its Heat Shock Protein (HSP) Platform (based on its HSP based technologies). The Company's key candidates from these technology platforms include QS-21 Stimulon adjuvant (QS-21), the Prophage Series vaccines and HerpV. The Company's products and technologies under development include QS-21. A number of pharmaceutical and biotechnology companies have licensed QS-21 from the Company for use in vaccines to treat a wide variety of human diseases. The Company has retained worldwide manufacturing rights for QS-21. It has the right to subcontract manufacturing for QS-21 and it has a supply agreement with a contract manufacturer for the production of QS-21 through September 2012. The Prophage Series vaccines describe its portfolio of patient-specific HSP-based therapeutic cancer vaccines, including the R-Series candidates in renal cell carcinoma (RCC), M-Series candidates in melanoma, and G-Series candidates in glioma.